大剂量甲氨蝶呤亚叶酸钙解救疗法治疗恶性肿瘤专家共识

2019-10-30 中国临床肿瘤学会 中国肿瘤临床.2019,46(15):761-767.

大剂量甲氨蝶呤亚叶酸钙解救(high dose methotrexate-calciumfolinate-rescue,HD-MTX-CFR)疗法中应用的MTX剂量属于致死量,在增加细胞毒作用提高抗肿瘤疗效的同时,也会出现极为严重的骨髓抑制及多脏器功能衰竭等损伤,合理的甲酰四氢叶酸钙(calcium folinate,CF)解救和水化碱化显得尤为关键。为提高HD-MTX化疗的临床疗效和安全性,规范

中文标题:

大剂量甲氨蝶呤亚叶酸钙解救疗法治疗恶性肿瘤专家共识

发布机构:

中国临床肿瘤学会

发布日期:

2019-10-30

简要介绍:

大剂量甲氨蝶呤亚叶酸钙解救(high dose methotrexate-calciumfolinate-rescue,HD-MTX-CFR)疗法中应用的MTX剂量属于致死量,在增加细胞毒作用提高抗肿瘤疗效的同时,也会出现极为严重的骨髓抑制及多脏器功能衰竭等损伤,合理的甲酰四氢叶酸钙(calcium folinate,CF)解救和水化碱化显得尤为关键。为提高HD-MTX化疗的临床疗效和安全性,规范CF解救的剂量和时间,中国临床肿瘤学会(CSCO)、CSCO抗白血病联盟、CSCO抗淋巴瘤联盟在参考国内外循证医学资料和相关指南的基础上,结合临床实践编写了此共识,供血液科、肿瘤科及儿科医生参考。

 

拓展指南:甲氨蝶呤相关指南:

相关资料下载:
[AttachmentFileName(sort=100, fileName=大剂量甲氨蝶呤亚叶酸钙解救疗法治疗恶性肿瘤专家共识)] GetToolGuiderByIdResponse(projectId=1, id=8481c1c001828600, title=大剂量甲氨蝶呤亚叶酸钙解救疗法治疗恶性肿瘤专家共识, enTitle=, guiderFrom=中国肿瘤临床.2019,46(15):761-767., authorId=null, author=, summary=大剂量甲氨蝶呤亚叶酸钙解救(high dose methotrexate-calciumfolinate-rescue,HD-MTX-CFR)疗法中应用的MTX剂量属于致死量,在增加细胞毒作用提高抗肿瘤疗效的同时,也会出现极为严重的骨髓抑制及多脏器功能衰竭等损伤,合理的甲酰四氢叶酸钙(calcium folinate,CF)解救和水化碱化显得尤为关键。为提高HD-MTX化疗的临床疗效和安全性,规范, cover=, journalId=null, articlesId=null, associationId=863, associationName=中国临床肿瘤学会, associationIntro=null, copyright=0, guiderPublishedTime=Wed Oct 30 00:00:00 CST 2019, originalUrl=, linkOutUrl=, content=<P>大剂量甲氨蝶呤亚叶酸钙解救(high dose methotrexate-calciumfolinate-rescue,HD-MTX-CFR)疗法中应用的MTX剂量属于致死量,在增加细胞毒作用提高抗肿瘤疗效的同时,也会出现极为严重的骨髓抑制及多脏器功能衰竭等损伤,合理的甲酰四氢叶酸钙(calcium folinate,CF)解救和水化碱化显得尤为关键。为提高HD-MTX化疗的临床疗效和安全性,规范CF解救的剂量和时间,中国临床肿瘤学会(CSCO)、CSCO抗白血病联盟、CSCO抗淋巴瘤联盟在参考国内外循证医学资料和相关指南的基础上,结合临床实践编写了此共识,供血液科、肿瘤科及儿科医生参考。 </P> <P> </P>拓展指南:<strong>与<font color=red>甲氨蝶呤</font>相关指南:</strong><br><ul><li><a href="https://www.medsci.cn/guideline/show_article.do?id=174e91c00161e187" title="2018 甲氨蝶呤治疗幼年特发性关节炎建议" target=_blank>2018 甲氨蝶呤治疗幼年特发性关节炎建议</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=31a961c00151a3d5" title="2017 共识指南:应用羧肽酶治疗高剂量甲氨蝶呤引起急性肾损伤以及甲氨蝶呤清除延迟患者" target=_blank>2017 共识指南:应用羧肽酶治疗高剂量甲氨蝶呤引起急性肾损伤以及甲氨蝶呤清除延迟患者</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=eb60c1c001a436eb" title="2016 BAD指南:皮肤疾病甲氨蝶呤处方用药的安全性和有效性" target=_blank>2016 BAD指南:皮肤疾病甲氨蝶呤处方用药的安全性和有效性</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=6335a1c00103167a" title="2013 AGA 炎性克罗恩病使用巯嘌呤类药物、甲氨蝶呤以及抗肿瘤坏死因子生物制剂诱导和维持缓解的临床指南" target=_blank>2013 AGA 炎性克罗恩病使用巯嘌呤类药物、甲氨蝶呤以及抗肿瘤坏死因子生物制剂诱导和维持缓解的临床指南</a></li> 更多信息请点击:<a href="https://www.medsci.cn/guideline/list.do?q=%E7%94%B2%E6%B0%A8%E8%9D%B6%E5%91%A4" target=_blank>有关甲氨蝶呤更多指南</a></ul>, tagList=[TagDto(tagId=1024, tagName=甲氨蝶呤), TagDto(tagId=3840, tagName=恶性肿瘤)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=20620, categoryName=肿瘤医学网, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=3, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=11016, appHits=333, showAppHits=17, pcHits=5818, showPcHits=7014, likes=82, shares=25, comments=4, approvalStatus=1, publishedTime=Tue Nov 19 22:08:33 CST 2019, publishedTimeString=2019-10-30, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Tue Nov 19 22:08:33 CST 2019, updatedBy=null, updatedName=null, updatedTime=Sat Jan 06 14:34:05 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=大剂量甲氨蝶呤亚叶酸钙解救疗法治疗恶性肿瘤专家共识)])
大剂量甲氨蝶呤亚叶酸钙解救疗法治疗恶性肿瘤专家共识
下载请点击:
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=906649, encodeId=f31090664942, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/tFIbqG99ULWomyW3q9TDNWhssrBa1C42kwt9ViaYyFDEZaPsW5uSkpdc5yQ7P9X63kiaRQzMr6durvzUyNNNULBw/132, createdBy=396a2268565, createdName=yumeng0126, createdTime=Thu Dec 10 10:50:03 CST 2020, time=2020-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894001, encodeId=08c1894001c1, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201016/ce079fd0944b4af0896c4bdb2d547ac3/73f2f6c2202b43ceb43dd2354f7f73e6.jpg, createdBy=dfab5426678, createdName=ms2000001622015603, createdTime=Fri Oct 23 20:24:41 CST 2020, time=2020-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883167, encodeId=f16088316ebf, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200908/f0fd4edbc73e4a3bb55ba748c002f51a/5bc7ce71ddc34e23947febcbe9bcaecd.jpg, createdBy=2a215316349, createdName=1489b237m71暂无昵称, createdTime=Sun Sep 06 22:27:44 CST 2020, time=2020-09-06, status=1, ipAttribution=)]
    2020-12-10 yumeng0126

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=906649, encodeId=f31090664942, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/tFIbqG99ULWomyW3q9TDNWhssrBa1C42kwt9ViaYyFDEZaPsW5uSkpdc5yQ7P9X63kiaRQzMr6durvzUyNNNULBw/132, createdBy=396a2268565, createdName=yumeng0126, createdTime=Thu Dec 10 10:50:03 CST 2020, time=2020-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894001, encodeId=08c1894001c1, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201016/ce079fd0944b4af0896c4bdb2d547ac3/73f2f6c2202b43ceb43dd2354f7f73e6.jpg, createdBy=dfab5426678, createdName=ms2000001622015603, createdTime=Fri Oct 23 20:24:41 CST 2020, time=2020-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883167, encodeId=f16088316ebf, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200908/f0fd4edbc73e4a3bb55ba748c002f51a/5bc7ce71ddc34e23947febcbe9bcaecd.jpg, createdBy=2a215316349, createdName=1489b237m71暂无昵称, createdTime=Sun Sep 06 22:27:44 CST 2020, time=2020-09-06, status=1, ipAttribution=)]
    2020-10-23 ms2000001622015603

    学习

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=906649, encodeId=f31090664942, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/tFIbqG99ULWomyW3q9TDNWhssrBa1C42kwt9ViaYyFDEZaPsW5uSkpdc5yQ7P9X63kiaRQzMr6durvzUyNNNULBw/132, createdBy=396a2268565, createdName=yumeng0126, createdTime=Thu Dec 10 10:50:03 CST 2020, time=2020-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894001, encodeId=08c1894001c1, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201016/ce079fd0944b4af0896c4bdb2d547ac3/73f2f6c2202b43ceb43dd2354f7f73e6.jpg, createdBy=dfab5426678, createdName=ms2000001622015603, createdTime=Fri Oct 23 20:24:41 CST 2020, time=2020-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883167, encodeId=f16088316ebf, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200908/f0fd4edbc73e4a3bb55ba748c002f51a/5bc7ce71ddc34e23947febcbe9bcaecd.jpg, createdBy=2a215316349, createdName=1489b237m71暂无昵称, createdTime=Sun Sep 06 22:27:44 CST 2020, time=2020-09-06, status=1, ipAttribution=)]
    2020-09-06 1489b237m71暂无昵称

    学习

    0